

Patient Celebrates 10 Years Since SynCardia's Total Artificial Heart



Tucson, AZ, April 17, 2024 - SynCardia Systems, LLC., a Picard Medical Company, proudly commemorates Steve William's remarkable 10-year journey since receiving a SynCardia Total Artificial Heart (TAH). Steve underwent the TAH implantation procedure on April 17, 2014.

Suffering from left ventricular hypertrophy and cardiomyopathy, Steve's health began to decline, impacting his beloved hobbies of tennis and golf. As his condition worsened, his lungs filled with fluid hindering his daily routine. On April 17, 2014, Steve underwent the TAH implantation, followed by a successful heart transplant a year later.

"April 17, 2024 is my 10-year anniversary of the TAH. Thank you to the donor, doctors, nurses, SynCardia, and friends and family," commented Steve Williams.

SynCardia Systems, LLC. is a leader in the development of total artificial hearts. The Company markets and sells the SynCardia Total Artificial Heart, which is the only US Food and Drug Administration (FDA) and Health Canada approved artificial heart. As of last year, the Company has implanted 2,080 SynCardia Total Artificial Hearts, including over 100 of the 50cc SynCardia Total Artificial Heart designed for smaller patients.

For more information about SynCardia and its Total Artificial Heart technology, please visit www.SynCardia.com



SynCardia Systems, LLC
1992 E. Silverlake Rd. Tucson, AZ 85713 | US
+1 520-545-1234 | info@syncardia.com
www.SynCardia.com



#SynCardia

About SynCardia Systems, LLC

Headquartered in Tucson, Ariz., SynCardia manufactures the world's only commercially approved Total Artificial Heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia Total Artificial Heart is the most widely used and extensively studied SynCardia Total Heart in the world.

By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn't an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).

SynCardia Systems, LLC – a Picard Medical Company

The SynCardia Total Artificial Heart is a treatment option for cardiac transplant-eligible patients at risk of imminent death from biventricular failure.

Medical Advice Disclaimer

The information, including but not limited to, text, graphics, images and other components contained in this material are for informational purposes only. No information in this material is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read in this material.

© SynCardia Systems, LLC | All rights reserved.